TCL Archive Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study December 26, 2014
TCL Archive In Brief: $100 Million Being Spent On Interferon In U.S., Rauscher Says; DeVita; Criticism Deserved April 4, 1980